Search research articles
Contact Us
Filters
Showing results (41-50 of 112) with videos related to
Page
of 12
Sort By:
Oncology
|
January 1, 1980
Effects of testosterone on estracyt localization in rat prostate
R Catane, A Mittelman, G P Murphy, et al.
Journal of Surgical Oncology
|
October 1, 1985
Radiation pneumonitis: a complication resulting from combined radiation and chemotherapy for early breast cancer
E Gez, A Sulkes, R Isacson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 6, 2009
European Society for Medical Oncology (ESMO) Program for the integration of oncology and Palliative Care: a 5-year review of the Designated Centers' incentive program
N Cherny, R Catane, D Schrijvers, et al.
Oncology
|
January 1, 1984
Procarbazine, CCNU and vincristine (PCV) combination chemotherapy for brain tumors
G Brufman, J Halpern, A Sulkes, et al.
Blood
|
August 15, 1990
Tuftsin induces tissue factor-like activity in human mononuclear cells and in monocytic cell lines
A Kornberg, R Catane, S Peller, et al.
Neurosurgery
|
February 1, 1988
Indomethacin and dexamethasone treatment in experimental neoplastic spinal cord compression: Part 1. Effect on water content and specific gravity
T Siegal, T Siegal, Y Shapira, et al.
Oncology
|
January 1, 1989
Chlorpromazine and dexamethasone versus high-dose metoclopramide and dexamethasone in patients receiving cancer chemotherapy, particularly cis-platinum: a prospective randomized crossover study
E Gez, R Ben-Yosef, R Catane, et al.
Natural Immunity and Cell Growth Regulation
|
January 1, 1990
Monoclonal antibodies against carcinoembryonic antigen (CEA) discriminate between CEA produced by gastrointestinal tumors and CEA produced by other tumors
R Catane, R Ben Yoseff, N Livni, et al.
Oncology
|
January 1, 1980
Chemotherapy of advanced, hormonally resistant prostatic carcinoma
S Madajewicz, R Catane, A Mittelman, et al.
Cancer Treatment Reports
|
November 1, 1979
Two-stage plans for patient accrual in phase II cancer clinical trials
Y J Lee, M Staquet, R Simon, et al.
Page
of 12
Search research articles
Search
Showing results (41-50 of 112) with videos related to
Sort By:
Page
of 12
Oncology
|
January 1, 1980
Effects of testosterone on estracyt localization in rat prostate
R Catane, A Mittelman, G P Murphy, et al.
Journal of Surgical Oncology
|
October 1, 1985
Radiation pneumonitis: a complication resulting from combined radiation and chemotherapy for early breast cancer
E Gez, A Sulkes, R Isacson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 6, 2009
European Society for Medical Oncology (ESMO) Program for the integration of oncology and Palliative Care: a 5-year review of the Designated Centers' incentive program
N Cherny, R Catane, D Schrijvers, et al.
Oncology
|
January 1, 1984
Procarbazine, CCNU and vincristine (PCV) combination chemotherapy for brain tumors
G Brufman, J Halpern, A Sulkes, et al.
Blood
|
August 15, 1990
Tuftsin induces tissue factor-like activity in human mononuclear cells and in monocytic cell lines
A Kornberg, R Catane, S Peller, et al.
Neurosurgery
|
February 1, 1988
Indomethacin and dexamethasone treatment in experimental neoplastic spinal cord compression: Part 1. Effect on water content and specific gravity
T Siegal, T Siegal, Y Shapira, et al.
Oncology
|
January 1, 1989
Chlorpromazine and dexamethasone versus high-dose metoclopramide and dexamethasone in patients receiving cancer chemotherapy, particularly cis-platinum: a prospective randomized crossover study
E Gez, R Ben-Yosef, R Catane, et al.
Natural Immunity and Cell Growth Regulation
|
January 1, 1990
Monoclonal antibodies against carcinoembryonic antigen (CEA) discriminate between CEA produced by gastrointestinal tumors and CEA produced by other tumors
R Catane, R Ben Yoseff, N Livni, et al.
Oncology
|
January 1, 1980
Chemotherapy of advanced, hormonally resistant prostatic carcinoma
S Madajewicz, R Catane, A Mittelman, et al.
Cancer Treatment Reports
|
November 1, 1979
Two-stage plans for patient accrual in phase II cancer clinical trials
Y J Lee, M Staquet, R Simon, et al.
Page
of 12